Joel Grubbs, DO
Family Medicine · Edmond, OKNPI 1649347501
Payments from drug & device makers
Across 422 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- AbbVie$1K
- AstraZeneca$648
- Lilly USA, LLC$563
- Novo Nordisk$561
- Amgen$523
- plus $2K from 29 others
What the payments were for
- Food & beverage$7,044100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 68 | $1,171 |
| AbbVie | 61 | $1,091 |
| AstraZeneca | 32 | $648 |
| Lilly USA, LLC | 40 | $563 |
| Novo Nordisk | 39 | $561 |
| Amgen | 26 | $523 |
| Boehringer Ingelheim | 27 | $366 |
| GSK | 21 | $329 |
| Merck | 26 | $282 |
| Corium, LLC | 10 | $229 |
| Sanofi-aventis U.S. LLC | 8 | $136 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $121 |
| Idorsia Pharmaceuticals US Inc | 6 | $106 |
| Exact Sciences | 6 | $104 |
| Ultragenyx Pharmaceutical Inc. | 4 | $86 |
| Abbott | 4 | $72 |
| Dexcom, Inc. | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| Shire North American Group Inc | 4 | $56 |
| Almatica Pharma LLC | 3 | $52 |
| Aimmune Therapeutics, Inc. | 2 | $51 |
| Antares Pharma, Inc. | 3 | $51 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| Arbor Pharmaceuticals, Inc. | 3 | $38 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| Genentech USA, Inc. | 2 | $36 |
| Nevro Corp. | 1 | $25 |
| Lundbeck LLC | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Adlon Therapeutics L.p. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,044 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 57 | $78,453 |
| MounjaroTirzepatide | 47 | $72,244 |
| EliquisApixaban | 35 | $54,174 |
| FarxigaDapagliflozin Propanediol | 33 | $49,589 |
| OzempicSemaglutide | 36 | $46,364 |
| TrulicityDulaglutide | 38 | $44,802 |
| RybelsusSemaglutide | 29 | $36,310 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $23,739 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $17,665 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $11,171 |
| OxycontinOxycodone Hcl | 11 | $9,645 |
| XareltoRivaroxaban | 17 | $8,887 |
| JanuviaSitagliptin Phosphate | 11 | $5,993 |
| Omeprazole | 147 | $2,599 |
| Levothyroxine Sodium | 191 | $2,469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $563 | $117,04685 claims |
| Novo NordiskOzempic, Rybelsus | $561 | $82,67465 claims |
| Boehringer IngelheimJardiance | $366 | $78,45357 claims |
| PfizerEliquis | $1,171 | $54,17435 claims |
| AstraZenecaFarxiga | $648 | $49,58933 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $329 | $34,91153 claims |
| Johnson & JohnsonXarelto | $17 | $8,88717 claims |
| MerckJanuvia | $282 | $5,99311 claims |
| AbbVieSynthroid | $1,091 | $1,93618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Edmond
- Stanley ShadidEdmond$363K
- Susan DimickEdmond$256K
- Charles WoodwardEdmond$15K
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.